Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
EV-to-OCF is calculated as enterprise value divided by its cash flow from operations. As of today, ACADIA Pharmaceuticals's Enterprise Value is $4,150 Mil.
ACADIA Pharmaceuticals's Cash Flow from Operations for the trailing twelve months (TTM) ended in Jun. 2026 was $160 Mil. Therefore, ACADIA Pharmaceuticals's EV-to-OCF for today is 25.89.
The historical rank and industry rank for ACADIA Pharmaceuticals's EV-to-OCF or its related term are showing as below:
ACAD'
s EV-to-OCF Range Over the Past 10 Years
Min: -145.56 Med: -16.61 Max: 276.44
Current: 25.89
During the past 13 years, the highest EV-to-OCF of ACADIA Pharmaceuticals was 276.44. The lowest was -145.56. And the median was -16.61.
ACAD's EV-to-OCF is ranked worse than 90.56% of 1409
companies
in the Biotechnology industry
Industry Median: -3.48
vs ACAD: 25.89
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
ACADIA Pharmaceuticals's PE Ratio (TTM) for today is calculated as:
ACADIA Pharmaceuticals's share price for today is $29.22.
ACADIA Pharmaceuticals's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $2.220.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Cash Flow from Operations is an important financial metric because it represents the cash generated from operating activities at a company's disposal. Companies with a low EV-to-OCF ratio, combined with a strong balance sheet are generally considered as undervalued.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, ACADIA Pharmaceuticals's EV-to-OCF, along with its competitors' market caps and EV-to-OCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
ACADIA Pharmaceuticals EV-to-OCF vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, ACADIA Pharmaceuticals's EV-to-OCF distribution charts can be found below:
* The bar in red indicates where ACADIA Pharmaceuticals's EV-to-OCF falls into.
ACADIA Pharmaceuticals's current Enterprise Value is $4,150 Mil.
ACADIA Pharmaceuticals's Cash Flow from Operations for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $160 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ACADIA Pharmaceuticals (ACAD) has a EV-to-OCF of 25.89 as of Aug. 08, 2026. According to the industry distribution chart, ACADIA Pharmaceuticals ranks #1276 out of 1409 companies in the Biotechnology industry, placing it in the top 90.6%.
Is ACADIA Pharmaceuticals' EV-to-OCF too high?
ACADIA Pharmaceuticals' current EV-to-OCF is 25.89. Based on the distribution chart, ACADIA Pharmaceuticals ranks #1276 out of 1409 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, ACADIA Pharmaceuticals has a GF Score™ of 80/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does ACADIA Pharmaceuticals' EV-to-OCF compare to LEGN and TNGX?
According to the Biotechnology industry distribution chart, ACADIA Pharmaceuticals ranks #1276 out of 1409 companies for EV-to-OCF. This places ACADIA Pharmaceuticals in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-OCF for a Biotechnology company?
A good EV-to-OCF depends on the Biotechnology industry context. However, EV-to-OCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-OCF mean?
A high EV-to-OCF can signal that a stock is expensive relative to its fundamentals. ACADIA Pharmaceuticals's current EV-to-OCF is 25.89. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ACADIA Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, ACADIA Pharmaceuticals (ACAD) is currently considered Modestly Overvalued. The stock's GF Value™ is $24.89, compared to a current price of $29.22 — trading 17.4% above its estimated fair value. The current EV-to-OCF is 25.89. ACADIA Pharmaceuticals' overall GF Score™ is 80/100 with 10 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-OCF calculated?
EV-to-OCF is calculated from a company's financial statements. For ACADIA Pharmaceuticals (ACAD), the current EV-to-OCF is 25.89 as of Aug. 08, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is ACADIA Pharmaceuticals (ACAD) Overvalued in 2026?
Based on GuruFocus' analysis, ACADIA Pharmaceuticals stock appears to be overvalued.
The current stock price of $29.22 is trading 17.4% above its estimated GF Value™ of $24.89.
GuruFocus considers ACADIA Pharmaceuticals to be Modestly Overvalued.
Key valuation signals for ACAD:
EV-to-OCF: 25.89
GF Value™: $24.89 vs. price of $29.22 (17.4% above fair value)
No single metric tells the full story. See the ACAD stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Acadia Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases. It has two core franchises in neuroscience and neuro-rare diseases. The neuroscience franchise is anchored by its commercial product NUPLAZID (pimavanserin), which is used for the treatment of hallucinations and delusions associated with Parkinson's Disease Psychosis (PDP). The neuro-rare disease franchise is anchored by the commercial product DAYBUE, which is used for the treatment of Rett syndrome. In addition, the company has various product candidates under development in different stages, including ACP-204, ACP-211, ACP-711, ACP-2591, etc.
80GF Score
Get the complete analysis for ACAD
EV-to-OCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ACAD has been successfully added to your 
